Biotechnologies Assets SA (BST.MC)

EUR 0.29

(-5.84%)

Total Debt Summary of Biotechnologies Assets SA

Biotechnologies Assets SA's latest annual total debt in 2023 was 7.12 Million EUR , up 91.64% from previous year.
Biotechnologies Assets SA's latest quarterly total debt in 2023 FY was 7.12 Million EUR , up 91.64% from previous quarter.
Biotechnologies Assets SA reported annual total debt of 3.71 Million EUR in 2022, up 3.95% from previous year.
Biotechnologies Assets SA reported annual total debt of 3.57 Million EUR in 2021, up 11.59% from previous year.
Biotechnologies Assets SA reported quarterly total debt of 7.12 Million EUR for 2023 Q4, up 74.03% from previous quarter.
Biotechnologies Assets SA reported quarterly total debt of 4 Million EUR for 2023 Q1, up 7.65% from previous quarter.

Annual Total Debt Chart of Biotechnologies Assets SA (2023 - 2010)

Historical Annual Total Debt of Biotechnologies Assets SA (2023 - 2010)

Year	Total Debt	Total Debt Growth
2023	7.12 Million EUR	91.64%
2022	3.71 Million EUR	3.95%
2021	3.57 Million EUR	11.59%
2020	3.2 Million EUR	-83.54%
2019	19.47 Million EUR	-58.4%
2018	46.8 Million EUR	3925.47%
2017	1.16 Million EUR	-0.62%
2016	1.16 Million EUR	-80.72%
2015	6.06 Million EUR	5.06%
2014	5.77 Million EUR	1156.01%
2013	459.84 Thousand EUR	23.13%
2012	373.46 Thousand EUR	0.0%
2011	- EUR	100.0%
2010	-7.34 EUR	0.0%

Year	Total Debt	Total Debt Growth
2023 Q2	3.8 Million EUR	-4.84%
2023 Q4	7.12 Million EUR	74.03%
2023 Q1	4 Million EUR	7.65%
2023 Q3	4.09 Million EUR	7.5%
2023 FY	7.12 Million EUR	91.64%
2022 FY	3.71 Million EUR	3.95%
2022 Q2	4.13 Million EUR	0.0%
2022 Q4	3.71 Million EUR	0.0%
2021 Q2	3.9 Million EUR	0.0%
2021 Q4	3.57 Million EUR	0.0%
2021 FY	3.57 Million EUR	11.59%
2020 FY	3.2 Million EUR	-83.54%
2020 Q2	22.97 Million EUR	0.0%
2020 Q4	3.2 Million EUR	0.0%
2019 FY	19.47 Million EUR	-58.4%
2019 Q4	19.47 Million EUR	0.0%
2019 Q2	21.94 Million EUR	0.0%
2018 FY	46.8 Million EUR	3925.47%
2018 Q4	46.8 Million EUR	0.0%
2018 Q2	17.87 Million EUR	0.0%
2017 Q4	1.16 Million EUR	0.0%
2017 FY	1.16 Million EUR	-0.62%
2017 Q2	1.21 Million EUR	0.0%
2016 Q2	1.15 Million EUR	0.0%
2016 Q4	1.16 Million EUR	0.0%
2016 FY	1.16 Million EUR	-80.72%
2015 Q4	6.06 Million EUR	0.0%
2015 FY	6.06 Million EUR	5.06%
2015 Q2	5.73 Million EUR	0.0%
2014 Q4	5.77 Million EUR	0.0%
2014 Q2	3.66 Million EUR	0.0%
2014 FY	5.77 Million EUR	1156.01%
2013 Q4	459.84 Thousand EUR	0.0%
2013 FY	459.84 Thousand EUR	23.13%
2013 Q2	382 Thousand EUR	0.0%
2012 Q2	4 Million EUR	0.0%
2012 FY	373.46 Thousand EUR	0.0%
2012 Q4	373.46 Thousand EUR	0.0%
2011 Q4	- EUR	0.0%
2011 Q2	3.59 Million EUR	0.0%
2011 FY	- EUR	100.0%
2010 FY	-7.34 EUR	0.0%
2010 Q4	-7.34 EUR	0.0%

Peer Total Debt Comparison of Biotechnologies Assets SA

Name	Total Debt	Total Debt Difference
Atrys Health, S.A.	254 Million EUR	97.195%
Oryzon Genomics S.A.	13.68 Million EUR	47.939%
Pharma Mar, S.A.	43.36 Million EUR	83.569%
Laboratorios Farmaceuticos Rovi, S.A.	65.42 Million EUR	89.109%